New lung cancer treatment shrinks some tumors: study
Monday 07 June 2010
A new experimental drug helps shrink tumors in lung cancer patients with a specific form of genetic alteration, according to results from a clinical trial unveiled Saturday.
The Pfizer Inc. drug crizotinib shrank tumors in patients with advanced non-small cell lung cancer (NSCLC) with a specific gene alteration of an enzyme implicated in cancer cell growth, known as anaplastic lymphoma kinase, or ALK.
According to Pfizer, around 10,000 people in the United States are affected by a lung cancer with this particular genetic mutation.
About 90 percent of the 82 participants in the small-scale Phase I clinical trial responded positively, and more than half - 57 percent - saw their tumors shrink after eight weeks, said lead author Yung-Jue Bang, a physician at Seoul National University College of Medicine.
Researchers had only expected about 10 percent of the patients, many of whom had already received three or more prior treatments, to respond to the treatment.
"These results are quite dramatic, and represent an important improvement over what we would see with standard chemotherapy for patients with metastatic disease," Bang told a news conference.
Most of the NSCLC patients were former smokers or never smoked. The median duration of treatment was approximately six months.
Crizotinib, which is taken orally, works by inhibiting the ALK enzyme. About one in 20 lung cancer patients in the United States are estimated to be diagnosed with ALK-positive NSCLC each year.
The genetic variation targeted by crizotinib affects about five percent of lung cancer patients. Each year, 12 million new cases of lung cancer are diagnosed worldwide and nearly eight million people die from the disease.
The study was presented at the American Society of Clinical Oncology conference, which is being held in Chicago this weekend.
Pfizer has begun a late-stage, or Phase III, trial to determine whether crizotinib improves the survival rate of ALK-positive lung cancer patients compared to standard chemotherapy treatment.
The Microsoft mogul told fans a few home truths during his Reddit AMA
First full-length look is finally here
Life & Style blogs
Snapchat removed the Best Friends list feature and 'stalkers' are upset
Baldness could soon be treated using stem cells, scientists hope
A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
Eight-year-old girl Camilla Lisant suggests possible cancer treatment to her scientist father over the dinner table
Lack of medically trained staff leaves NHS 111 phone service struggling to cope, insider claims
- 1 Woman falls to her death as she celebrates marriage proposal at the edge of Ibiza cliff
- 2 Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
- 3 Ball pool for adults opens in London
- 4 Baldness could soon be treated using stem cells, scientists hope
- 5 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
£12500 - £13000 per annum: Recruitment Genius: The largest independent Reprogr...
£6240 per annum: Recruitment Genius: This company is a well established websit...
£120 - £145 per day: Tradewind Recruitment: French & German Teacher X2 Materni...
£25000 - £32500 per annum: Recruitment Genius: Based in SW London, this compan...